NRICM101

A Traditional Chinese Medicine formulation.

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Natural product

1
Supporting references
0
Contradictory references
1
Clinical trials

General information

NRICM101 is a raditional Chinese Medicine decoction, which contains multiple bioactive compounds. It experimentally showes anti-inflammatory and anti-SARS-CoV-2 properties (Tsai et al., 2020). Its composition for a daily dose is: Scutellaria Root (Scutellaria baicalensis, HA, 18.75 g), Heartleaf Houttuynia (Houttuynia cordata, HC, 18.75 g), Mulberry Leaf (Morus alba, NB, 11.25 g), Saposhnikovia Root (Saposhnikovia divaricata, NC, 7.50 g), Mongolian Snakegourd Fruit (Trichosanthes kirilowii, ND, 18.75 g), Indigowoad Root (Isatis indigotica, NE, 18.75 g), baked Liquorice Root (Glycyrrhiza glabra, NG, 7.50 g), Magnolia Bark (Magnolia officinalis, NK, 11.25 g), Peppermint Herb (Mentha haplocalyx, NL, 11.25 g), and Fineleaf Nepeta (Nepeta tenuifolia, NR, 11.25 g). 


Synonyms

Taiwan Chingguan Yihau


Supporting references

Link Tested on Impact factor Notes Publication date DB entry date
A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study
Biophysical assay Animal model In vitro Mixed substance Cohort study
in vitro biophysical assay; Vero E6 cells; murine alveolar macrophages (LPS-induced inflammation model); Patients 4.55

The formulation was administered to patients who did not have 3 negative tests for SARS-CoV-2 after 21.5 days (median) of standard hospital care. These patients reached the negativity in 9 days (median) after intervention. NRICM101 bound RBD of SARS-CoV-2 Spike protein and impeded the Spike-ACE2 interaction in vitro. It also reduced SARS-CoV-2 replication in vitro and decreased IL-6 and TNF-α levels in a LPS-induced inflammation model. Sample size (patients): 12. Dosage (patients): 100 mL 30 minutes after meal three times daily until discharge.

Nov/19/2020 Dec/03/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04664049 The Outcomes of NRICM101 on SARS-COV-2 (COVID-19) Infection Recruiting Dec/23/2020 Dec/31/2022